Live Breaking News & Updates on Institutional Investors Weigh In On Supernus Pharmaceuticals

Stay updated with breaking news from Institutional investors weigh in on supernus pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a hold rating to a buy rating in a report released on Wednesday. Separately, Piper Sandler raised their price target on shares of Supernus Pharmaceuticals from $42.00 to $43.00 and gave the company an overweight rating in a research report on Thursday, November 9th. […] ....

United States , Piper Sandler , Frank Mottola , Frederickm Hudson , Supernus Pharmaceuticals Inc , News Ratings For Supernus Pharmaceuticals Daily , Health Asset Management , Insider Transactions At Supernus Pharmaceuticals , Institutional Investors Weigh In On Supernus Pharmaceuticals , Supernus Pharmaceuticals Stock Performance , Dimensional Fund Advisors , Supernus Pharmaceuticals , Burney Co , Mirabella Financial Services , International Biotechnology Trust , Free Report , Get Free Report , Director Frederick , Biotechnology Trust , Fund Advisors , Financial Services , Supernus Pharmaceuticals Daily , Nasdaq Supn , Stocknews Com ,

Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Lowered to Hold at StockNews.com

StockNews.com downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a hold rating in a research note released on Friday morning. Separately, Piper Sandler lowered their target price on Supernus Pharmaceuticals from $43.00 to $42.00 and set an overweight rating on the stock in a research note on Wednesday, October […] ....

United States , Piper Sandler , Tami Tillotson Martin , Supernus Pharmaceuticals Trading , Tower Research Capital , Supernus Pharmaceuticals , Institutional Investors Weigh In On Supernus Pharmaceuticals , Insider Activity At Supernus Pharmaceuticals , Supernus Pharmaceuticals Inc , Supernus Pharmaceuticals Company Profile , Mendota Financial Group , News Ratings For Supernus Pharmaceuticals Daily , Free Report , Get Free Report , Tillotson Martin , Jacobson Investment Advisors , Employees Retirement System , Financial Group , Research Capital , Supernus Pharmaceuticals Daily , Nasdaq Supn , Stocknews Com ,

Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 52-Week Low Following Analyst Downgrade

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Free Report)’s stock price reached a new 52-week low during trading on Wednesday after StockNews.com downgraded the stock from a buy rating to a hold rating. The company traded as low as $23.34 and last traded at $23.46, with a volume of 45380 shares trading hands. The stock had […] ....

United States , Piper Sandler , Tami Tillotson Martin , Stephens Investment Management Group , Blackrock Inc , News Ratings For Supernus Pharmaceuticals Daily , Securities Exchange Commission , Supernus Pharmaceuticals Stock Down , Supernus Pharmaceuticals , Dimensional Fund Advisors , Macquarie Group Ltd , Vanguard Group Inc , Institutional Investors Weigh In On Supernus Pharmaceuticals , Supernus Pharmaceuticals Inc , Get Free Report , Tillotson Martin , Exchange Commission , Fund Advisors , Investment Management Group , Pharmaceuticals Stock Down , Supernus Pharmaceuticals Daily , Nasdaq Supn ,

Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Buy at StockNews.com

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Thursday. Separately, Piper Sandler reduced their target price on shares of Supernus Pharmaceuticals from $46.00 to $43.00 in a research report on Wednesday, July 26th. Check Out […] ....

United States , Tami Tillotson Martin , Piper Sandler , Institutional Investors Weigh In On Supernus Pharmaceuticals , Norges Bank , Supernus Pharmaceuticals , Pacer Advisors Inc , Supernus Pharmaceuticals Stock Performance , Blackrock Inc , Supernus Pharmaceuticals Inc , News Ratings For Supernus Pharmaceuticals Daily , Bellevue Group , Millennium Management , Get Free Report , Tillotson Martin , Supernus Pharmaceuticals Daily , Nasdaq Supn , Stocknews Com ,

Supernus Pharmaceuticals (NASDAQ:SUPN) Posts Earnings Results

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) released its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.17, Briefing.com reports. Supernus Pharmaceuticals had a net margin of 9.10% and a return on equity of 7.12%. The firm had revenue of […] ....

Frank Mottola , Jacka Khattar , Piper Sandler , Supernus Pharmaceuticals Inc , Earnings History For Supernus Pharmaceuticals , Securities Exchange Commission , Institutional Investors Weigh In On Supernus Pharmaceuticals , Supernus Pharmaceuticals , Metlife Investment Management , Insider Transactions At Supernus Pharmaceuticals , News Ratings For Supernus Pharmaceuticals Daily , Sei Investments Co , Supernus Pharmaceuticals Stock , Get Rating , Exchange Commission , Montreal Can , Life Investment Management , Sei Investments , Supernus Pharmaceuticals Daily , Nasdaq Supn ,